Skip to main content

Table 1 Clinical and bronchoalveolar lavage details of the study groups

From: Tumour necrosis factor-α production in fibrosing alveolitis is macrophage subset specific

  

Age (years):

Smoking

 

%Fluid recovery

Total BAL cells (× 105 /ml):

%Macr.:

%Lymph.:

%Neutr.:

% Eosin.:

Patients

Sex (M:F)

median (range)

(S:EX:NS)

Treatment

median (range)

median (range)

median (range)

median (range)

median (range)

median (range)

CFA (n = 9)

5 : 4

60.0 (46–70)

2 : 5 : 3

2

46.6 (12.7–63.3)

1.37 (0.6–5.2)

85.0 (72–92)

5.0 (0–17)

5.0 (2–15)

1.0 (0–4)

FASSc (n = 9)

3 : 6

48.0 (27–68)

0 : 3 : 6

3

53.3 (25.0–72.0)

1.07 (0.1–2.1)

87.0 (67–93)

10.0 (3–25)

3.0 (1–8)

0.0 (0–4)

SSc no FA (n = 10)

3 : 7

47.0 (27–57)

0 : 4 : 6

1

49.2 (11.6–65.0)

0.82 (0.2–6.7)

91.0 (62–98)

9.0 (2–11)

1.0 (0–2.9)

0.0 (0–2)

Normal (n = 10)

7 : 3

30.0 (28–34)

1 : 1 : 8

0

58.8 (46.6–81.0)

0.9 (0.1–3.4)

92.5 (73–98)

7.0 (2–26)

0.5 (0–3)

0.5 (0–1)

  1. CFA = cryptogenic fibrosing alveolitis; Eosin = eosinophils; EX = ex-smoker, stopped at least 12 months; F = female; FASSc = fibrosing alveolitis associated with systemic sclerosis; Lymph = lymphocytes; M = male; Macr = macrophages; Neutr = neutrophils; NS = nonsmoker; S = current smoker; SSc = systemic sclerosis.